Research programme: antibody therapeutics - Philogen

Drug Profile

Research programme: antibody therapeutics - Philogen

Alternative Names: Dodecal; F8-IL12; F8-IL4; Tetravil

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator Philogen
  • Class Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 12 stimulants; Interleukin 4 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Endometriosis; Rheumatoid arthritis

Most Recent Events

  • 20 Jan 2016 Preclinical trials in Cancer in Italy (Parenteral) before January 2016 (Philogen website, January 2016)
  • 20 Jan 2016 Preclinical trials in Endometriosis in Italy (Parenteral) before January 2016 (Philogen Pipeline, January 2016)
  • 20 Jan 2016 Philogen plans clinical trials for Rheumatoid arthritis and Endometriosis in Europe (Parenteral) (Philogen website, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top